Federico Rodriguez-Porcel
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 9 | 2023 | 272 | 2.730 |
Why?
|
| Lewy Body Disease | 3 | 2022 | 9 | 1.230 |
Why?
|
| Movement Disorders | 3 | 2022 | 58 | 1.020 |
Why?
|
| Prion Diseases | 1 | 2019 | 5 | 0.700 |
Why?
|
| Basal Ganglia Diseases | 1 | 2016 | 13 | 0.540 |
Why?
|
| Cerebral Cortex | 2 | 2016 | 415 | 0.500 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2016 | 91 | 0.480 |
Why?
|
| Supranuclear Palsy, Progressive | 2 | 2022 | 6 | 0.420 |
Why?
|
| REM Sleep Behavior Disorder | 3 | 2022 | 4 | 0.410 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2011 | 26 | 0.390 |
Why?
|
| Hypotension, Orthostatic | 2 | 2021 | 15 | 0.360 |
Why?
|
| Social Behavior | 1 | 2011 | 164 | 0.360 |
Why?
|
| Antidepressive Agents | 1 | 2011 | 216 | 0.350 |
Why?
|
| Behavior, Animal | 2 | 2011 | 470 | 0.340 |
Why?
|
| Antiparkinson Agents | 3 | 2021 | 34 | 0.270 |
Why?
|
| Humans | 21 | 2023 | 68618 | 0.250 |
Why?
|
| Mutation | 2 | 2019 | 1213 | 0.220 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2021 | 86 | 0.210 |
Why?
|
| Neuropsychological Tests | 2 | 2021 | 517 | 0.200 |
Why?
|
| Parkinsonian Disorders | 2 | 2022 | 43 | 0.190 |
Why?
|
| Executive Function | 1 | 2021 | 106 | 0.180 |
Why?
|
| Temporal Lobe | 1 | 2021 | 125 | 0.180 |
Why?
|
| Myoclonus | 1 | 2019 | 9 | 0.180 |
Why?
|
| Language | 1 | 2020 | 120 | 0.170 |
Why?
|
| Dopamine | 1 | 2021 | 474 | 0.160 |
Why?
|
| Cognition | 1 | 2023 | 513 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 2223 | 0.160 |
Why?
|
| Research Design | 1 | 2023 | 729 | 0.160 |
Why?
|
| White Matter | 1 | 2021 | 174 | 0.160 |
Why?
|
| Apathy | 1 | 2018 | 28 | 0.150 |
Why?
|
| Affective Symptoms | 1 | 2018 | 50 | 0.150 |
Why?
|
| Hydrocephalus, Normal Pressure | 1 | 2017 | 5 | 0.150 |
Why?
|
| Dopamine Agonists | 1 | 2018 | 68 | 0.150 |
Why?
|
| Stroke | 2 | 2022 | 2163 | 0.150 |
Why?
|
| Deep Brain Stimulation | 1 | 2018 | 71 | 0.150 |
Why?
|
| Aphasia, Primary Progressive | 1 | 2016 | 4 | 0.140 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 102 | 0.140 |
Why?
|
| Somatoform Disorders | 1 | 2016 | 35 | 0.140 |
Why?
|
| Dystonia | 1 | 2016 | 18 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 146 | 0.130 |
Why?
|
| Fatal Outcome | 1 | 2016 | 164 | 0.130 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 137 | 0.130 |
Why?
|
| Serotonin | 2 | 2011 | 144 | 0.120 |
Why?
|
| Seizures | 1 | 2016 | 279 | 0.120 |
Why?
|
| Depression | 2 | 2018 | 943 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2020 | 7277 | 0.110 |
Why?
|
| Epilepsy | 1 | 2016 | 336 | 0.100 |
Why?
|
| Male | 8 | 2021 | 37321 | 0.100 |
Why?
|
| Middle Aged | 6 | 2021 | 21147 | 0.100 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2011 | 54 | 0.100 |
Why?
|
| Rats, Long-Evans | 1 | 2011 | 203 | 0.090 |
Why?
|
| Locomotion | 1 | 2011 | 135 | 0.090 |
Why?
|
| Animals, Newborn | 1 | 2011 | 396 | 0.090 |
Why?
|
| Aged | 6 | 2021 | 14862 | 0.080 |
Why?
|
| Female | 7 | 2021 | 38074 | 0.070 |
Why?
|
| Rats | 2 | 2011 | 5300 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1851 | 0.070 |
Why?
|
| Pregnancy | 1 | 2011 | 2334 | 0.060 |
Why?
|
| Disease Progression | 2 | 2019 | 1038 | 0.060 |
Why?
|
| Prevalence | 2 | 2020 | 1619 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 58 | 0.050 |
Why?
|
| Time and Motion Studies | 1 | 2021 | 16 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 84 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2022 | 122 | 0.050 |
Why?
|
| Atrophy | 1 | 2021 | 112 | 0.050 |
Why?
|
| Task Performance and Analysis | 1 | 2021 | 150 | 0.050 |
Why?
|
| Child | 1 | 2011 | 6405 | 0.050 |
Why?
|
| England | 1 | 2020 | 64 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2022 | 782 | 0.040 |
Why?
|
| Attention | 1 | 2021 | 225 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 700 | 0.040 |
Why?
|
| Postural Balance | 1 | 2019 | 93 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 848 | 0.040 |
Why?
|
| PubMed | 1 | 2017 | 21 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2022 | 565 | 0.040 |
Why?
|
| Animals | 2 | 2011 | 20881 | 0.040 |
Why?
|
| Biomarkers | 1 | 2022 | 1593 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2077 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 159 | 0.030 |
Why?
|
| Levodopa | 1 | 2016 | 12 | 0.030 |
Why?
|
| Family Health | 1 | 2016 | 83 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 2279 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 176 | 0.030 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2016 | 138 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2016 | 418 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1864 | 0.030 |
Why?
|
| Anxiety | 1 | 2016 | 422 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1553 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 4848 | 0.020 |
Why?
|
| Autistic Disorder | 1 | 2011 | 77 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 2358 | 0.020 |
Why?
|
| Homeostasis | 1 | 2011 | 291 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 2007 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 7029 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1174 | 0.020 |
Why?
|
| Adult | 1 | 2016 | 21403 | 0.010 |
Why?
|